

Title: Economic Evaluation of Transitioning to the 20-valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme



Authors: Esra Çakar,¹ An Ta,² Michel Peters,¹ Elizabeth Vinand,² Angela Waterval-Overbeek,¹ Aleksandar Ilic,³ and Johnna Perdrizet⁴

Affiliations: 1. Pfizer BV, Capelle aan den IJssel, Netherlands; 2. Cytel, United Kingdom; 3. Pfizer UK, Tadworth, United Kingdom; 4. Global Value and Evidence, Pfizer Canada, Kirkland, QC, Canada

Corresponding author: Johnna Perdrizet; Johnna.Perdrizet@pfizer.com; Pfizer Canada, 17300 Trans-Canada Hwy, Kirkland, QC, Canada, H9J 2M5.


Supplementary materials

Supplementary Figure 1. PSA convergence plots, a) costs and b) QALYs



Abbreviations: PCV15, 15-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year.

Supplementary Figure 2. PSA ellipse plot



Abbreviations: CI, confidence interval; PCV15, 15-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; PSA, probabilistic sensitivity analysis.